MX2016001193A - Medicamento que comprende anticuerpo anti-fosfolipasa d4. - Google Patents
Medicamento que comprende anticuerpo anti-fosfolipasa d4.Info
- Publication number
- MX2016001193A MX2016001193A MX2016001193A MX2016001193A MX2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A
- Authority
- MX
- Mexico
- Prior art keywords
- phospholipase
- present application
- pld4
- medicaments
- application provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013158258 | 2013-07-30 | ||
| PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001193A true MX2016001193A (es) | 2016-05-26 |
Family
ID=51493000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001193A MX2016001193A (es) | 2013-07-30 | 2014-07-30 | Medicamento que comprende anticuerpo anti-fosfolipasa d4. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160168266A1 (zh) |
| EP (1) | EP3027656B1 (zh) |
| JP (3) | JP6431523B2 (zh) |
| KR (1) | KR102367760B1 (zh) |
| CN (1) | CN105745226B (zh) |
| AU (1) | AU2014297217B2 (zh) |
| BR (1) | BR112016002001B1 (zh) |
| CA (1) | CA2919736C (zh) |
| DK (1) | DK3027656T3 (zh) |
| ES (1) | ES2736324T3 (zh) |
| HU (1) | HUE044469T2 (zh) |
| MX (1) | MX2016001193A (zh) |
| PL (1) | PL3027656T3 (zh) |
| RU (1) | RU2709741C2 (zh) |
| SG (2) | SG10201800592SA (zh) |
| TR (1) | TR201910330T4 (zh) |
| WO (1) | WO2015016386A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2809683B1 (en) * | 2012-01-31 | 2018-10-03 | SBI Biotech Co., Ltd. | Anti-phospholipase d4 antibody |
| CN117330747A (zh) | 2016-07-15 | 2024-01-02 | 武田药品工业株式会社 | 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料 |
| JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型ｔｌｒ７の分析 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE196606T1 (de) * | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| WO2000011015A1 (en) * | 1998-08-24 | 2000-03-02 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
| US20020146686A1 (en) * | 2000-12-07 | 2002-10-10 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
| JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
| EP2809683B1 (en) * | 2012-01-31 | 2018-10-03 | SBI Biotech Co., Ltd. | Anti-phospholipase d4 antibody |
-
2014
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active IP Right Grant
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 MX MX2016001193A patent/MX2016001193A/es unknown
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en active Application Filing
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014297217A1 (en) | 2016-02-18 |
| CN105745226A (zh) | 2016-07-06 |
| US20160168266A1 (en) | 2016-06-16 |
| JP2019214621A (ja) | 2019-12-19 |
| JP6431523B2 (ja) | 2018-11-28 |
| CN105745226B (zh) | 2020-03-06 |
| CA2919736A1 (en) | 2015-02-05 |
| EP3027656A1 (en) | 2016-06-08 |
| DK3027656T3 (da) | 2019-08-05 |
| WO2015016386A1 (en) | 2015-02-05 |
| ES2736324T3 (es) | 2019-12-27 |
| AU2014297217B2 (en) | 2020-01-16 |
| SG10201800592SA (en) | 2018-03-28 |
| RU2016106708A (ru) | 2017-09-01 |
| BR112016002001A2 (pt) | 2017-08-29 |
| CA2919736C (en) | 2022-03-22 |
| KR102367760B1 (ko) | 2022-02-24 |
| BR112016002001B1 (pt) | 2023-04-25 |
| JP2016534022A (ja) | 2016-11-04 |
| EP3027656B1 (en) | 2019-06-26 |
| RU2709741C2 (ru) | 2019-12-19 |
| PL3027656T3 (pl) | 2019-10-31 |
| KR20160034934A (ko) | 2016-03-30 |
| HUE044469T2 (hu) | 2019-10-28 |
| JP6843449B2 (ja) | 2021-03-17 |
| SG11201600666SA (en) | 2016-02-26 |
| US20210130493A1 (en) | 2021-05-06 |
| RU2016106708A3 (zh) | 2018-03-30 |
| JP2019014759A (ja) | 2019-01-31 |
| TR201910330T4 (tr) | 2019-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501120B1 (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
| EA201391564A1 (ru) | Полипептиды антитела, которые антагонизируют cd40 | |
| EP4249065A3 (en) | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors | |
| EA201300133A1 (ru) | Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
| EA201690503A1 (ru) | Антитела | |
| IN2015KN00350A (zh) | ||
| TR201908367T4 (tr) | Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi | |
| EA201300137A1 (ru) | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| BR112016002401A8 (pt) | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| EA201300131A1 (ru) | Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями | |
| EA201590061A1 (ru) | Фармацевтическая композиция | |
| WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| BR112018015090A2 (zh) | Thrombin antibody, antigen-binding fragment thereof and pharmaceutical use |